Comparison of Dexlansoprazole-based Triple and Rabeprazole-based Triple Therapies for Helicobacter Pylori Infection
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
Dexlansoprazole MR is the R-enantiomer of lansoprazole that is delivered by a dual delayed
release formulation. It is effective for symptom control of patients with gastroesophageal
reflux disease. However, its efficacy in the treatment of H.pylori infection remains unclear.
This study was conducted to investigate whether the efficacy of single-dose dexlansoprazole
MR-based triple therapy was non-inferior to double-dose rabeprazole-based triple therapy in
the treatment of H.pylori infection.